



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

(C)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/900,112	07/05/2001	Mario H. Skiadopoulos	NIH-0127	5747
7590	05/04/2004		EXAMINER	
JEFFREY J. KING, ESQ. GRAYBEAL JACKSON HALEY LLP 155 - 108th AVENUE, N.E., SUITE 350 BELLEVUE, WA 98004-5901			SCHEINER, LAURIE A	
			ART UNIT	PAPER NUMBER
			1648	

DATE MAILED: 05/04/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)
	09/900,112	SKIADOPoulos ET AL.
Examiner	Art Unit	
Laurie A. Scheiner	1648	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 06 November 2003.

2a) This action is **FINAL**. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1-84 is/are pending in the application.
4a) Of the above claim(s) 49-57,82 and 83 is/are withdrawn from consideration.
5) Claim(s) _____ is/are allowed.
6) Claim(s) 1-48,58-81 and 84 is/are rejected.
7) Claim(s) _____ is/are objected to.
8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) All b) Some * c) None of:
1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. _____.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) Notice of References Cited (PTO-892)
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date 10/31/02.

4) Interview Summary (PTO-413)
Paper No(s)/Mail Date. ____.
5) Notice of Informal Patent Application (PTO-152)
6) Other: ____.

Art Unit: 1648

Applicant's election of Group I (claims 1-48, 58-81 and 84) on November 6, 2003 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)). Claims 49-57, 82 and 83 are withdrawn from consideration as being drawn to a non-elected invention.

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(e) the invention was described in-
(1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effect under this subsection of a national application published under section 122(b) only if the international application designating the United States was published under Article 21(2)(a) of such treaty in the English language; or

Claims 1-48, 58-81 and 84 are rejected under 35 U.S.C. 102(e) as being anticipated by Murphy et al. (WO98/53078).

Murphy et al. teach recombinant PIV genomes and antigenomes for production of recombinant PIV comprising N, P, L and modification of biologically derived PIV mutants. Chimeric human-bovine PIVs are also taught. The infectious PIV particles can be viral or subparticle in nature. The isolated particles are produced by partial or complete deletions or substitutions of non-essential genes, such as F, HN, M and C. The PIV can be HPIV (types 1-3), and the sequences therein can be incorporated into the HPIV background genome or antigenome, such as the cytoplasmic tail and the transmembrane domain. Other modifications may include nucleotide insertions, rearrangements, deletions, substitutions, attenuation, temperature -sensitivity, cold-adaptation, small plaque size, host range restriction, or a change in

Art Unit: 1648

an immunogenic epitope in PIV. Recombinant PIV having multiple phenotypic mutations introduced in the background genome or antigenome, such as HPIV3 JS cp45. Target genes for mutation include N, P, L, M, HN, F, C, D and V open reading frame products; other mutations are also taught, as are methods of administration to humans.


Claims 1-48, 58-81 and 84 are rejected under 35 U.S.C. 102(e) as being anticipated by Belshe et al. (US Patent No. 5,869,036)

Belshe et al. teach an isolated cp-45 hybrid which may be employed as a vaccine in humans. The reference teaches that the gene sequence which encodes the surface glycoproteins of the target virus may be substituted for the corresponding sequence in the cp45 genome which codes for the HN and F proteins, resulting in a chimeric genome.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Laurie Scheiner, whose telephone number is (571) 272-0910. Due to a flexible work schedule, the examiner's hours typically vary each day. However, the examiner can normally be reached Monday thru Friday. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Housel, can be reached on (571) 272-0902.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group 1600 receptionist whose telephone number is (571) 272-1600.

Correspondence related to this application may be submitted to Group 1600 by facsimile transmission. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). Official communications should be directed toward the following central fax number: (703) 872-9306.


Laurie Scheiner/LAS
April 20, 2004

LAURIE SCHEINER
PRIMARY EXAMINER